On September 23, 2024, Judge Kleeh of the Northern District of West Virginia denied Regeneron Pharmaceuticals, Inc.’s ...

Regeneron Pharmaceutical (NASDAQ:REGN) fell 2% after a court rejected its request for a temporary injunction blocking sales ...

The FDA recently approved Amgen’s biosimilar of Eylea — Pavblu. This is the fifth biosimilar approved for Eylea. The FDA had ...

Injection 2 mg and does not impact EYLEA HD® (aflibercept) Injection 8 mg. We continue to believe that Amgen is infringing our patent rights, and today’s decision denying our request for a ...

Amgen (NASDAQ: AMGN) stock is up 13% this year but has struggled to break out above a tight trading range in recent months. Despite a string of solid earnings reports from the biotechnology giant ...

Amgen on Tuesday reported that a pair of antibody drugs it is developing as treatments for immune-mediated diseases succeeded in late-stage trials, but the therapies did not clearly beat existing ...

Salveen Richter has given his Buy rating due to a combination of factors that highlight Amgen’s potential growth prospects. A critical focus is on the upcoming Phase 2 obesity data for MariTide ...

The FDA recently approved Amgen’s biosimilar of Eylea — Pavblu. This is the fifth biosimilar approved for Eylea. The FDA had earlier approved Biocon Biologics's Yesafili (aflibercept-jbvf) and Samsung ...